Last reviewed · How we verify

Farletuzumab, Carboplatin, and PLD

Morphotek · Phase 1 active Small molecule

Farletuzumab, Carboplatin, and PLD is a Small molecule drug developed by Morphotek. It is currently in Phase 1 development. Also known as: Farletuzumab (MORAb-003), Carboplatin, PLD.

At a glance

Generic nameFarletuzumab, Carboplatin, and PLD
Also known asFarletuzumab (MORAb-003), Carboplatin, PLD
SponsorMorphotek
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Farletuzumab, Carboplatin, and PLD

What is Farletuzumab, Carboplatin, and PLD?

Farletuzumab, Carboplatin, and PLD is a Small molecule drug developed by Morphotek.

Who makes Farletuzumab, Carboplatin, and PLD?

Farletuzumab, Carboplatin, and PLD is developed by Morphotek (see full Morphotek pipeline at /company/morphotek).

Is Farletuzumab, Carboplatin, and PLD also known as anything else?

Farletuzumab, Carboplatin, and PLD is also known as Farletuzumab (MORAb-003), Carboplatin, PLD.

What development phase is Farletuzumab, Carboplatin, and PLD in?

Farletuzumab, Carboplatin, and PLD is in Phase 1.

Related